Newsworthy


January 2021

Glaucoma and Genetics Come Into Focus


December 2020

Dr. John received the Sanford and Susan Greenberg Visionary Prize to End Blindness 20/20

Please read more at the following links:

PR Newswire

Columbia University Department of Ophthalmology

People Magazine

National Geographic (subscription required)

Awards Ceremony


New metabolic treatment strategies for glaucoma

Paper published in Proceedings of the National Academy of Sciences (PNAS). We discover further metabolic disturbances that contribute to glaucoma vulnerability. We expand the treatment options by showing that both pyruvate or rapamycin are protective against glaucoma. This builds on our concept of metabolic and resilience boosting treatments.


December 2019

Simon John joins the Department of Ophthalmology at Columbia University


April 2018

An Eye for Research


May 2017

Preserving Metabolic Function in Glaucoma

Further work from the John lab demonstrating that metabolism supporting, Resilence-based treatments are effectice against glaucoma. We that treatment with vitamin B3 enhances the effects of gene-based therapeutic interventions and protects from all assessed measures of glaucoma.


April 2017

Providing a Clearer View On Glaucoma Processes

Paper published in Proceedings of the National Academy of Sciences (PNAS) suggests that immune changes occur very early following IOP elevation and prior to any detected retinal ganglion cell dysfunction. The research provides evidence that astrocytes protect retinal ganglion cells during periods of increased pressure in the eye via a pathway involving complement C3.


February 2017

Vitamin B3 Prevents Glaucoma

A breakthrough paper demonstrating metabolic abnormalities in glaucoma. We show that NAD boosting treatments, including gene therapy, are potently protective in an inherited mouse model of glaucoma. This work led to the concept of Resilience-boosting treatments that enhance bioenergetic and other cellular resources to prevent glaucoma.